Renowned oncologist, Professor Fred R. Hirsch, MD, PhD, has accepted the nomination to the Board of Directors of CHOSA
Oct 04, 2024
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Today, on 04 October 2024, we are happy to communicate that the renowned oncologist, Professor Fred R. Hirsch, MD, PhD, has accepted the nomination to the Board of Directors of CHOSA. Dr. Hirsch brings a wealth of experience and a strong background in oncology, research, and leadership to the Board of Directors.
Professor Hirsch currently serves as the Executive Director of the Center for Thoracic Oncology and Co-Director of the Center of Excellence for Thoracic Oncology at The Tisch Cancer Institute (TCI) at Mount Sinai. He also holds the title of Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai and acts as the Associate Director of Biomarker Discovery for TCI.
With over 18 years as a Professor of Medicine and Pathology at the University of Colorado and five years as CEO of the International Association for the Study of Lung Cancer (IASLC), Dr. Hirsch has been at the forefront of translational research in thoracic oncology. He has received numerous awards, including the IASLC Mary Matthews Award for Translational Research in Lung Cancer (2007), the Japanese Lung Cancer Society Merit Award (2010), the Addario Foundation Lecture Award (2015), and the Wuan Ki Hong Lectureship Award (2019).
Professor Hirsch’s extensive contribution to lung cancer research includes over 400 publications in peer-reviewed journals, establishing him as an internationally renowned authority in the field. His participation in the CHOSA board will bring invaluable expertise in thoracic oncology and biomarkers.
“I am honored to be able to attract Professor Hirsch for the CHOSA board. Professor Hirsch is one of the most renowned and respected lung cancer experts. For five years, he served as the CEO of the International Association for the Study of Lung Cancer (IASLC), a global organization comprising over 10,000 doctors and experts dedicated to advancing lung cancer therapy.
Cisplatin and carboplatin play pivotal roles in lung cancer treatment, and precision in their application is key to improving cure rates”, said MD, DMSc and CEO Peter Buhl Jensen
“Our collaborators and future customers include doctors and nurses, and our strategy to engage and collaborate with key opinion leaders in oncology is greatly supported by Fred’s expertise and involvement.
I look very much forward to Professor Hirsch’s contribution to our mission to improve cancer care and research,” Peter Buhl Jensen further commented.
For more information on Dr. Fred R. Hirsch and his nomination for the CHOSA Board, please contact
For additional information, contact:
Peter Buhl Jensen, CEO
Peter@chosa.bio
+ 45 21 60 89 22
CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of LiPlaCis® and the DRP®.
About Cisplatin-DRP, a test to predict if cisplatin treatment is likely to be successful
CHOSA is focused on late-stage clinical development of LiPlaCis® and its DRP® drug response predictor to which it has worldwide rights. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. Breast: We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment.
Lung: The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cisplatin therapy after surgery is a gold standard that increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer, especially in new neoadjuvant treatment where immunotherapy obtains high efficacy rates when combined with cisplatin doubles. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.
Immunotherapy There is a new development that adds further value to our DRP. Cisplatin has often been shown to activate the immune system (making cold tumors hot), which makes tumors susceptible to PD1 inhibitors. This synergy is particularly important but not limited to the treatment of lung cancer, bladder cancer, and head and neck cancer. In the ever-growing PD1 inhibitor market, where competition is fierce, our company stands out with the ability to predict if cisplatin will provide synergy with PD1. This can give the PD1 selling companies a significant competitive advantage.
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.
